Last reviewed · How we verify
Colloidal pectin bismuth particles A quadruple therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Colloidal pectin bismuth particles A quadruple therapy (Colloidal pectin bismuth particles A quadruple therapy) — Xijing Hospital of Digestive Diseases.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Colloidal pectin bismuth particles A quadruple therapy TARGET | Colloidal pectin bismuth particles A quadruple therapy | Xijing Hospital of Digestive Diseases | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Colloidal pectin bismuth particles A quadruple therapy CI watch — RSS
- Colloidal pectin bismuth particles A quadruple therapy CI watch — Atom
- Colloidal pectin bismuth particles A quadruple therapy CI watch — JSON
- Colloidal pectin bismuth particles A quadruple therapy alone — RSS
Cite this brief
Drug Landscape (2026). Colloidal pectin bismuth particles A quadruple therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/colloidal-pectin-bismuth-particles-a-quadruple-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab